Epidemiological evidence indicates that individuals with dyslipidemia frequently exhibit a pro-inflammatory state, characterized by elevated concentrations of inflammatory cytokines such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and interleukin-6 (IL-6), which further stimulate hs-CRP production [11,12]. This evidence concerns the gene IL6 and metabolic syndrome.